doi:10.3969/j.issn.1006-7795.2021.04.026

Abstract

CLC Number:

R737.9

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.04.026

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I4/672

[1] Bragy F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[2] DeSantis C E, Fedewa S A, Goding Sauer A, et al. Breast cancer statistics, 2015: convergence of incidence rates between black and white women [J]. CA Cancer J Clin, 2016, 66(1): 31-42.
[3] 中国乳腺癌内分泌治疗专家共识专家组. 中国乳腺癌内分泌治疗专家共识(2015年版) [J]. 中国癌症杂志, 2015, 25(9): 755-759.
[4] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2):115-132.
[5] 马飞,徐兵河,邵志敏,等. 乳腺癌随访及伴随疾病全方位管理指南 [J]. 中华肿瘤杂志, 2019, 41(1): 29-41.
[6] Gradishar W J, Anderson B O, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2020, 18(4): 452-478.
[7] Hancock M J . Appraisal of Clinical Practice Guideline: Early and locally advanced breast cancer: diagnosis and management. NICE guideline [NG101] [J]. J Physiother, 2019,65(1):57.
[8] Nelson H D, Fu R, Zakher B, et al. Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force[J]. JAMA, 2019, 322(9):868-886.
[9] Buzdar A. The place of chemotherapy in the treatment of early breast cancer [J]. Br J Cancer, 1998, 78 Suppl 4 (Suppl 4): 16-20.
[10] Early Breast Cancer Trialist's Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J]. Lancet, 2011, 378(9793): 771-784.
[11] Burstein H J, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update [J]. J Clin Oncol, 2014, 32(21): 2255-2269.
[12] Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [J]. Lancet, 2013, 381(9869): 805-816.
[13] 刘强, 李舜颖. 乳腺癌内分泌治疗是否已全面进入十年时代? [J]. 中华乳腺病杂志(电子版), 2017, 11(1): 1-5.
[14] Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [J]. J Natl Cancer Inst, 1996, 88(21): 1529-1542.
[15] 徐兵河, 冯继锋, 胡夕春,等. 早期激素受体阳性乳腺癌患者应用选择性雌激素受体调节剂类药物辅助治疗的长期管理中国专家共识[J]. 中华医学杂志, 2016, 96(40):3201-3205.
[16] No author listed. Committee Opinion No. 601: Tamoxifen and uterine cancer [J]. Obstet Gynecol, 2014, 123(6): 1394-1397.
[17] No author listed. Practice Bulletin No. 149: Endometrial cancer [J]. Obstet Gynecol, 2015, 125(4): 1006-1026.
[18] 中国抗癌协会妇科肿瘤专业委员会. 子宫肉瘤诊断与治疗指南(第四版) [J]. 中国实用妇科与产科杂志, 2018, 34(10): 1106-1110.
[19] Engin H. High-grade endometrial stromal sarcoma following tamoxifen treatment [J]. Gynecol Oncol, 2008, 108(1): 253-254.
[20] Fleming C A, Heneghan H M, O'Brien D, et al. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy [J]. Br J Surg, 2018, 105(9): 1098-1106.
[21] Marshall K, Senior J. A study on the effect of a single dose of tamoxifen on uterine hyperaemia and growth in the rat [J]. Br J Pharmacol, 1987, 92(2): 429-435.
[22] Schweikart K M, Eldridge S R, Safgren S L, et al. Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats [J]. Toxicol Pathol, 2014, 42(8): 1188-1196.
[23] Ismail S M. Pathology of endometrium treated with tamoxifen [J]. J Clin Pathol, 1994, 47(9): 827-833.
[24] Fisher D E. Apoptosis in cancer therapy: crossing the threshold [J]. Cell, 1994, 78(4): 539-542.
[25] Berliere M, Charles A, Galant C, et al. Uterine side effects of tamoxifen: a need for systematic pretreatment screening [J]. Obstet Gynecol, 1998, 91(1): 40-44.
[26] Chalas E, Costantino J P, Wickerham D L, et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial [J]. Am J Obstet Gynecol, 2005, 192(4): 1230-1239.
[27] Berlière M, Radikov G, Galant C, et al. Identification of women at high risk of developing endometrial cancer on tamoxifen [J]. Eur J Cancer, 2000, 36 Suppl 4:S35-36.
[28] Cheng W F, Lin H H, Torng P L, et al. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients [J]. Gynecol Oncol, 1997, 66(2): 233-237.
[29] Fisher B, Costantino J P, Wickerham D L, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [J]. J Natl Cancer Inst, 1998, 90(18): 1371-1388.
[30] 子宫内膜癌筛查专家委员会. 子宫内膜癌筛查和早期诊断专家共识(草案) [J]. 中国实用妇科与产科杂志, 2017, 33(10): 1050-1052.
[31] Wolfman W. No. 249-asymptomatic endometrial thickening[J]. J Obstet Gynaecol Can, 2018, 40(5): e367-e377.
[32] Fung M F, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen [J]. Gynecol Oncol, 2003, 91(1): 154-159.
[33] Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding [J]. Ultrasound Obstet Gynecol, 2004, 24(5): 558-565.
[34] Fishman M, Boda M, Sheiner E, et al. Changes in the sonographic appearance of the uterus after discontinuation of tamoxifen therapy [J]. J Ultrasound Med, 2006, 25(4): 469-473.
[35] Fong K, Kung R, Lytwyn A, et al. Endometrial evaluation with transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen [J]. Radiology, 2001, 220(3): 765-773.
[36] Gultekin I B, Imamoglu G I, Gultekin S,et al. Elastosonographic evaluation of endometrium in women using tamoxifen for breast cancer [J]. Niger J Clin Pract, 2019, 22(1): 92-100.
[37] Giannella L, Mfuta K, Setti T, et al. Diagnostic accuracy of endometrial thickness for the detection of intra-uterine pathologies and appropriateness of performed hysteroscopies among asymptomatic postmenopausal women [J]. Eur J Obstet Gynecol Reprod Biol, 2014, 177:29-33.
[38] Gerber B, Krause A, Muller H, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound [J]. J Clin Oncol, 2000, 18(20): 3464-3470.
[39] 中国抗癌协会妇科肿瘤专业委员会. 子宫内膜癌诊断与治疗指南(第四版) [J]. 中国实用妇科与产科杂志 2018, 34(8): 880-886.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhao Yue, Ruan Xiangyan, Cheng Jiaojiao, Gu Muqing, Xu Xin, Wang Yuejiao. Breast cancer pathological diagnosis reveals correlation between progesterone receptor membrane component 1 and clinicopathological parameters [J]. Journal of Capital Medical University, 2022, 43(3): 350-356.
[2]	Wei Changsheng, Luo Chengyu, Zhang Shuqi. Application of periareolar incision combined with mastoscopic axillary lymph node dissection in breast conserving surgery for early breast cancer [J]. Journal of Capital Medical University, 2021, 42(6): 1014-1020.
[3]	Yang Yang, Kang Hua, Zhao Jing, Ling Yuwei, Zhao Ye, Wang Yajun, Rong Dongdong. Retrospective analysis of preoperative breast MRI of breast cancer patients with breast conserving surgery [J]. Journal of Capital Medical University, 2020, 41(6): 943-953.
[4]	Bai Xiangdong, Hao Yating, Zhang Xinxue, He Qiang. Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients [J]. Journal of Capital Medical University, 2019, 40(6): 911-915.
[5]	Wang Yuejiao, Ruan Xiangyan, Gu Muqing, Cai Guiju, Li Xue, Zhang Lingyan, Alfred O. Mueck. Tamoxifen treated breast cancer xenograft in nude mice and uterine pathological changes [J]. Journal of Capital Medical University, 2019, 40(4): 539-543.
[6]	Chen Nina, Fan Yichang, Shang Kun, Yang Jing, Cao Bangwei. Serum lipid and apolipoprotein levels were associated to the Ki-67 and molecular classification of breast cancer [J]. Journal of Capital Medical University, 2019, 40(2): 191-194.
[7]	Xu Quan, Liu Yujie, Pan Yu, Zheng Xiuyuan, Liu Jingmin, Sun Xiaohua, Zou Lili, Ma Lina, Yan Hongsong. Effects of bioelectrical impedance test frequency on quantitative assessment of breast cancer associated lymphedema [J]. Journal of Capital Medical University, 2018, 39(5): 747-751.
[8]	Peng Nan, Liu Huimin, Wang Weixin, Liu Ming, Wang Zhiqun. Multi-parameters quantitative analysis of breast infiltrating ductal carcinoma as measured by diffusion weighted imaging and dynamic enhancement [J]. Journal of Capital Medical University, 2018, 39(2): 190-194.
[9]	Wang Lijuan, Yang Chun, Gu Muqing, Pierre Hardy, Ruan Xiangyan, Alfred O. Mueck. Relationship between progesterone-regulated microRNAs and breast cancer [J]. Journal of Capital Medical University, 2017, 38(4): 521-525.
[10]	Gu Muqing, Yang Chun, Wang Lijuan, Pierre Hardy, Jia Chanwei, Ruan Xiangyan. Current research studies of the relationship between miR-181a and breast cancers [J]. Journal of Capital Medical University, 2017, 38(4): 526-529.
[11]	Luo Chengyu. A paradigm shift from standard to precisely minimal invasion in breast cancer. [J]. Journal of Capital Medical University, 2016, 37(3): 331-335.
[12]	Wang Zihan, Teng Changsheng, Ge Zhicheng, Zhang Huiming, Yuan Zhu, Gao Yinguang, Zhang Zhongtao, Qu Xiang. Single port laparoscopic breast-conserving surgery in treatment of breast cancer [J]. Journal of Capital Medical University, 2016, 37(3): 336-340.
[13]	Cui Zhimiao, Luo Chengyu, Li Xin, Liu Baoyin, Ding Yi. Clinical application of nipple areola complex sparing modified mastoscopic mastectomy with one-stage reconstruction [J]. Journal of Capital Medical University, 2016, 37(3): 341-345.
[14]	Zhang Ying, Ruan Xiangyan, Mi Xin, Wang Gangyue, Alfred O. Mueck. Study of prognostic impact of progesterone receptor membrane component 1 (PGRMC1) in breast cancer patients [J]. Journal of Capital Medical University, 2015, 36(4): 548-552.
[15]	ZHANG Ying, RUAN Xiangyan, TIAN Xuanxuan, ZHANG Junli, Alfred O. Mueck. Development of progesterone receptor membrane component 1(PGRMC1) on the risk of breast cancer [J]. Journal of Capital Medical University, 2013, 34(4): 496-500.